Press Releases
All Pfizer published press releases by date and/or category of news
06.23.2023 Prescription Medicines Medicines FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata 06.22.2023 Financial Finance Pfizer Declares Third-Quarter 2023 Dividend 06.20.2023 Prescription Medicines Medicines Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
Media Asset Library
A collection of assets for use by media.
Partnering News
The latest news from Pfizer and its strategic partners
12.01.2022 Corporate Partnerships Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases 11.10.2022 Corporate Partnerships Fox Chase Cancer Center and Sylvester Comprehensive Cancer Center Collaborate with Pfizer’s Institute of Translational Equitable Medicine to Identify Novel Genetic Drivers of Cancer Disparities in African Ancestry Populations
Media Contacts
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Media Contacts
General email
[email protected]
United States, Canada and Latin America
+1 212.733.1226
Europe, the Middle East and Africa
+44-(0)173.733.2335
[email protected]
Asia Pacific
+65.918.732.47
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Other Frequently Visited Links
For more, see these helpful and often used sections of Pfizer.com
Pfizer Wire
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.